Ruth Puig-Peiro

• AstraZeneca
• Innovation
• Multi-Indication Therapies
• Pricing and Reimbursement
• Combination Therapies
• Drug Development/R&D
• Health Technology Assessment…
• Precision Medicine
• Use of Medicines
• Value-Based Pricing

Payment Models for Multi-Indication Therapies

Read more

• Determining Value
• England
• Epidemiology and Public Health
• External Publications
• NHS
• Pfizer
• Healthcare Systems
• Vaccines

The Value of Vaccines in Maintaining Health System Capacity in England

Read more

• HTA
• PhRMA
• Health Technology Assessment…

How is Quality of Life Measured for Health Technology Assessments?

Read more

• ABPI
• Determining Value
• Infectious Diseases
• NHS
• UK
• COVID-19 Research
• Health Technology Assessment…
• Vaccines

Realising The Broader Value of Vaccines in the UK: Ready for Prime Time?

Read more

• Clinical Outcomes
• EuroQol

Drop Dead: Is Anchoring at ‘Dead’ a Theoretical Requirement in Health State Valuation?

Read more